Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma

References

• Furge KA, MacKeigan JP, Teh BT. Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol 2010;11:571-8
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. The TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. The AVOREN Trial Investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8
   PubMed Web of Science ®Google Scholar
• Fabian MA, Biggs WH, III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Case S. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 2010;15:236-45
   PubMed Web of Science ®Google Scholar
• NCCN. Clinical practice guidelines in oncology: kidney cancer. Fort Washington, NY: National Comprehensive Cancer Network, 2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed March 13, 2012
   Google Scholar
• Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics 2011;29:977-88
   PubMed Web of Science ®Google Scholar
• Marshall D, Bridges JFP, Hauber AB, et al. Conjoint analysis applications in health–how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Patient 2010;3:249-56
   PubMedGoogle Scholar
• Bridges JFP, Kinter ET, Kidane L, et al. Things are looking up since we started listening to patients: trends in the application of conjoint analysis in health 1982-2007. Patient 2008;1:273-82
   PubMedGoogle Scholar
• Hauber AB, Mohamed AF, Beam C, et al. Patient preferences and assessment of likely adherence to hepatitis C virus treatments. J Viral Hepat 2011;18:619-27
   PubMed Web of Science ®Google Scholar
• Hauber AB, Mohamed AF, Watson ME, et al. Benefits, risk, and uncertainty: preferences of antiretroviral-naïve African Americans for HIV treatments. AIDS Patient Care STDS 2009;23:29-34
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. The common terminology criteria for adverse events (CTCAE), version 4.0. Bethesda, MD: National Cancer Institute, 2009. http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5x7.pdf. Accessed November 21, 2011.
   Google Scholar
• Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health-a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011;14:403-11
   PubMed Web of Science ®Google Scholar
• Kuhfeld W. Marketing research methods in SAS: experimental design, choice, conjoint, and graphical techniques. Cary, NC: SAS Institute Inc., 2010
   Google Scholar
• Kuhfeld W, Tobias F, Garratt M. Efficient experimental design with marketing research applications. J Mark Res 1994;31:545-57
   Web of Science ®Google Scholar
• Train K. Mixed logit. In: Train K, ed. Discrete choice methods with simulation. Cambridge: Cambridge University Press, 2003
   Google Scholar
• Train K, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Scarpa R, Alberini A, eds. Applications of simulation methods in environmental and resource economics. Dordrecht: Springer Publisher, 2005
   Google Scholar
• Hensher DA, Rose JM, Greene WH. Applied choice analysis. Cambridge: Cambridge University Press, 2005
   Google Scholar
• Bech M, Gyrd-Hansen D. Effects coding in discrete choice experiments. Health Econ 2005;14:1079-83
   PubMed Web of Science ®Google Scholar
• Dillman DA, Smyth JD, Christian LM. Internet, mail, and mixed-mode surveys: the tailored design method. Hoboken, NJ: John Wiley & Sons, Inc., 2009
   Google Scholar
• Louviere JJ, Hensher DA, Swait JD. Stated choice methods: analysis and applications. New York: Cambridge University Press, 2000
   Google Scholar